Prognostic role of programmed cell death ligand-1 expression in head and neck cancer treated with programmed cell death protein-1/programmed cell death ligand-1 inhibitors: A meta-analysis based on clinical trials
Conclusions: In summary, PD-L1–positive HNSCC patients portend favorable OS at 6 and 12 months from PD-1/PD-L1 ICIs. Increased ORR also favored to appear in PD-L1 expressors of HNC or recurrent/metastatic HNSCC who received PD-1/PD-L1 ICIs. Therefore, PD-L1 proved to be an appropriate biomarker to predict the clinical efficacy and prognosis of PD-1/PD-L1 ICIs in HNC.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Zilu Huang Shuohan Zheng Shirong Ding Yinghong Wei Chen Chen Xing Liu He Li Yunfei Xia Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Databases & Libraries | Head and Neck Cancer | HNSCC | Skin Cancer | Squamous Cell Carcinoma | Study